Amy Ciccarella
Research Subjects
Research Interests
Amy Ciccarella has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Amy Miskimon Goss
Department of Nutrition Sciences, The University of Alabama at Birmingham , Birmingham, AL 35294
1 shared publication - Arlene A. Stecenko
Division of Pulmonary, Asthma, Cystic Fibrosis, and Sleep; Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA
1 shared publication - Chris Driggers
Division of Pulmonary, Asthma, Cystic Fibrosis, and Sleep; Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA
1 shared publication - Heather Zhou
Bionutrition Research Unit, Emory University Hospital Georgia Clinical and Translational Science Alliance Clinical Research Center, Emory University School of Medicine, Atlanta, Georgia, USA
1 shared publication - Jessica A. Alvarez
Division of Endocrinology, Lipids, and Metabolism, Department of Medicine, Emory University School of Medicine, USA
1 shared publication - Joshua D. Chandler
Division of Pulmonology, Asthma, Cystic Fibrosis and Sleep, Department of Pediatrics, Emory University School of Medicine, USA
1 shared publication
Latest Publications
- Open Access
Low-added sugar dietary intervention study to mitigate glucose intolerance and improve body composition in adults with cystic fibrosis: a protocol of a double-blind, randomised study
Introduction People with cystic fibrosis (PwCF) are at high risk for developing cystic fibrosis (CF)-related diabetes (CFRD), which worsens morbidity and mortality. Although the pathological events leading to the development of CFRD are complex and not completely understood, dietary factors may play a role. For example, habitual intake of dietary added sugar (i.e., sugar not naturally occurring in foods) has been shown to be increased in PwCF and this excess intake of added sugar could increase the risk of CFRD. Methods and analysis/design The goal of this ongoing double-blind, randomised, parallel-group clinical trial is to recruit approximately 60 clinically stable adults with CF to determine if a low-added sugar intervention improves beta-cell responsiveness and insulin sensitivity (Aim 1), reduces visceral adipose tissue (VAT) and other ectopic fat deposition (Aim 2) and improves plasma redox status (Aim 3) over 8 weeks compared with a typical CF diet. All foods will be provided. Participant selection criteria include confirmed CF diagnosis without CFRD, ≥18 years of age, and baseline estimated daily total added sugar intake >16 tsp. Eligible participants will be randomised to one of two arms: a low-added sugar diet (Ethics and dissemination The National Institutes of Health (NIH) funds this study (R01 DK133523). The study protocol was approved by the Emory Institutional Review Board (IRB approval number: 000004517). Any protocol modifications will be reviewed and approved by the IRB prior to implementation and communicated with the study team and participants, as relevant. We will provide reports of the findings to the NIH and Emory IRB in regular progress reports and post the findings on www.Clinicaltrials.gov. We will inform the findings of the study to the scientific community through presentations and peer-reviewed publications. Authorship for any resulting publications will follow the guidelines established by the International Committee of Medical Journal Editors. Trial registration number This research study is registered at www.Clinicaltrials.gov (NCT05766774).
Open AccessLow-added sugar dietary intervention study to mitigate glucose intolerance and improve body composition in adults with cystic fibrosis: a protocol of a double-blind, randomised study
Introduction People with cystic fibrosis (PwCF) are at high risk for developing cystic fibrosis (CF)-related diabetes (CFRD), which worsens morbidity and mortality. Although the pathological events leading to the development of CFRD are complex and not completely understood, dietary factors may play a role. For example, habitual intake of dietary added sugar (i.e., sugar not naturally occurring in foods) has been shown to be increased in PwCF and this excess intake of added sugar could increase the risk of CFRD. Methods and analysis/design The goal of this ongoing double-blind, randomised, parallel-group clinical trial is to recruit approximately 60 clinically stable adults with CF to determine if a low-added sugar intervention improves beta-cell responsiveness and insulin sensitivity (Aim 1), reduces visceral adipose tissue (VAT) and other ectopic fat deposition (Aim 2) and improves plasma redox status (Aim 3) over 8 weeks compared with a typical CF diet. All foods will be provided. Participant selection criteria include confirmed CF diagnosis without CFRD, ≥18 years of age, and baseline estimated daily total added sugar intake >16 tsp. Eligible participants will be randomised to one of two arms: a low-added sugar diet (Ethics and dissemination The National Institutes of Health (NIH) funds this study (R01 DK133523). The study protocol was approved by the Emory Institutional Review Board (IRB approval number: 000004517). Any protocol modifications will be reviewed and approved by the IRB prior to implementation and communicated with the study team and participants, as relevant. We will provide reports of the findings to the NIH and Emory IRB in regular progress reports and post the findings on www.Clinicaltrials.gov. We will inform the findings of the study to the scientific community through presentations and peer-reviewed publications. Authorship for any resulting publications will follow the guidelines established by the International Committee of Medical Journal Editors. Trial registration number This research study is registered at www.Clinicaltrials.gov (NCT05766774).